Hydroxytyrosol inhibits the inflammatory response of osteoarthritis chondrocytes. - GreenMedInfo Summary
Hydroxytyrosol inhibits the inflammatory response of osteoarthritis chondrocytes via SIRT6-mediated autophagy.
Mol Med Rep. 2018 Mar ;17(3):4035-4042. Epub 2017 Dec 27. PMID: 29286133
Osteoarthritis (OA) is a common degenerative joint disease. Inflammation may exaggerate the catabolism and degeneration in the pathogenesis of OA. Hydroxytyrosol (HT) has been used in the management of inflammatory diseases. In addition, reports have revealed that autophagy was a therapeutic target of diseases caused by inflammation. Sirtuin 6 (SIRT6) has also been demonstrated to prevent OA development by reducing both the inflammatory response and chondrocyte senescence. However, the roles of SIRT6 and autophagy in cartilage and its underlying anti‑inflammatory mechanism are unknown. Therefore, the present study aimed to determine the effects of HT on autophagy and inflammation in chondrocytes, and clarify whether HT regulates the inflammatory response through SIRT6‑mediated autophagy. The expression of protein and mRNA were determined bywestern blot analysis and reverse transcription‑quantitative polymerase chain reaction. The production of cytokines was detected by ELISA. It was demonstrated that HT inhibited the levels of interleukin (IL)‑1β and IL‑6 in tumor necrosis factor (TNF)‑α‑stimulated chondrocytes in a concentration‑dependent manner. In addition, HT promoted cell autophagy and increased the mRNA and protein expression levels of SIRT6 in chondrocytes stimulated with TNF-α. Autophagy inhibitor 3-methyladenine or knockdown of SIRT6 decreased the inhibitory effects of HT on the inflammatory response inchondrocytes. In addition, knockdown of SIRT6 attenuated the expression of microtubule-associated protein 1A/1B‑light chain 3 and Beclin1 in chondrocytes. Overall, these findings suggested that HT inhibits the inflammatory response of chondrocytes through SIRT6‑mediated autophagy. The present study provided a new drug target for the clinical treatment of inflammatory diseases.